- Market Research
- Stocks Research
- ETF Research
- Mutual Funds Research
- Options Research
- Bonds & Fixed Income Research
Stock Research
Stock Quotes & Research Tools
View our stock quotes and sample our research offering.
Try our powerful stock tools to help compare investments and get ideas.
Find out about our industry leading research providers.
| Last Price | Today's Change | Today's Volume |
|---|---|---|
| $1,008.39 | +18.06 (1.82%) | 111,344Below Average |
Details | |
|---|---|
| Today's Open | $986.50 |
| Previous Close | $990.33 |
| Day's Range | $980.58 - $1,008.93 |
| 52 Week range | $623.78 - $1,133.95 |
| Beta | 0.46 |
| Avg. Volume (10 Day) | 2,938,231 |
| Put/Call Ratio (1 Day) | 4.1 |
| Put/Call Ratio (30 Day) | 5.9 |
Dividends | |
|---|---|
| Quarterly Div. (Ann. Yield) | $1.73 (0.70%) |
| Next Ex-Date | Feb 13, 2026 |
| Next Pay Date | Mar 10, 2026 |
Shares | |
|---|---|
| Market Capitalization (Large Cap) | $934.2B |
| Shares Outstanding | 943.4M |
| Shares Held By Institutions | 83% |
- 3:13 PM ETReuters
(Updates to add details in paragraphs 1 and 2)March ?9 (Reuters) - Eli Lilly said on Monday asmall...
- 2:47 PM ETReuters
(Adds company context in paragraphs 2, 4, 6, 9, analyst commentin paragraph 18)* Hims to sell FDA...
- 12:55 PM ETReuters
(Changes dateline, updates with CSL's expansion)March 9 (Reuters) - Global drugmakers are ramping...
- 11:20 AM ETReuters
(Adds analyst comments)By Padmanabhan AnanthanMarch 9 (Reuters) - U.S. drugmaker ?Pfizer saidon...
- 10:50 AM ETReuters
March 9 (Reuters) - Eli Lilly said on Monday asmall ?number of basic Medicare drug plans ?may not...
- UPDATE 3-Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
- Form PRE 14A ELI LILLY & Co For: Mar 06
- UPDATE 2-Drugmaker Aspen expects full-year double-digit profit growth after decline in first half
- Fake Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens
- Global Business Leaders Explore Responsible Leadership in an Era of Shared Challenges
- Global Business Leaders Explore Responsible Leadership in an Era of Shared Challenges
- Form PRE 14A ELI LILLY & Co For: Mar 06
- Form 4 ELI LILLY & Co For: Feb 19 Filed by: Dozier Eric
- Form 4 ELI LILLY & Co For: Feb 17 Filed by: Sulzberger Gabrielle
View the rationale behind our Schwab Equity Rating with details on what factors and components contribute to the overall rating.
Qualitative analysis on Morningstar’s global equity coverage. Analyst commentary, star ratings and economic moat evaluations.
This report contains the Argus rating and qualitative assessment of a stock's investment potential.
CFRA's Stock Reports contain equity analysis covering 5,000 publicly traded companies. The reports provide CFRA's ranking and qualitative opinion, financial statistics, and up to 10 years of summary balance sheet and income statement data.
Detailed financials and consensus ratings from Refinitiv.
Manage market risk with quantitative technical analysis models from Market Edge.
Quotes are delayed by at least 15 minutes. Before trading, please check a real-time quote for current information.
Important Disclosures
Schwab Equity Ratings and other materials are for informational purposes only and is not an offer to sell or the solicitation of an offer to buy. Schwab Equity Ratings and the general buy/sell/hold guidance are not personal recommendations for any particular investor or client and do not take into account the financial, investment or other objectives or needs of, and may not be suitable for any particular investor or client. Before buying, investors and clients should consider whether the investment is suitable. Investors and clients should consider Schwab Equity Ratings as only a single factor in making their investment decision while taking into account the current market environment.
Schwab Equity Ratings utilize third-party data in the forming of a rating. Data is obtained from what are considered reliable sources; however, its accuracy, completeness or reliability cannot be guaranteed. Schwab Equity Ratings are generally updated weekly, so you should review and consider any recent market or company news before taking any action. Stocks may go down as well as up and investors (including clients) may lose money, including their original investment. Past performance is no indication of future results and returns are not guaranteed. For individualized advice, please contact Schwab at 1 (877) 284-9817. Note: An asterisk (*) next to a Schwab Equity Rating means that a potentially significant even has been announced for an A or B rated stock, Although Schwab generally does not monitor C, D, and F rated stocks for current news, from time to time, asterisks may appear on a particular stock due to certain circumstances (e.g. the downgrade of a stock from a B to C rating).
The news sources used on Schwab.com come from independent third parties. Schwab is not affiliated with any of the news content providers. Schwab is not responsible for the content, and does not write or control which particular article appears on its website. The securities markets (1) reserve all rights to the market data that they make available; (2) do not guarantee that data; and (3) shall not be liable for any loss due either to their negligence or to any cause beyond their reasonable control.